Vol 8, No 4 (2023)
Case report
Published online: 2023-09-14
Breast apocrine carcinoma: a case report and review of literature
1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1
DOI: 10.5603/mrj.96297
Medical Research Journal 2023;8(4):312-316.
Abstract
Breast cancer is known to be the most common malignancy in women worldwide, the spectrum of the
histological type varies from common types as invasive ductal carcinoma, of no special type to a rare
variety as apocrine breast carcinoma. This study reports a case of apocrine carcinoma in a 60-year-old
female patient, exploring the diagnosis strategies and management of this case.
Keywords: breast apocrine carcinomaandrogen receptorschemotherapyradiotherapy
References
- Wader JV, Jain A, Bhosale SJ, et al. Apocrine carcinoma of breast: a case report with review of the literature. Case Rep Pathol. 2013; 2013: 170918.
- Tan PH, Ellis I, Allison K, et al. WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020; 77(2): 181–185.
- Khan KA, Alkistawi F, Idaewor P, et al. Breast atypical apocrine adenosis: a case report and literature review. Cureus. 2020; 12(6): e8624.
- Barron M, Asaad A, Idaewor P, et al. Breast apocrine carcinoma detected incidentally as axillary lymphadenopathy in a CT scan. Cureus. 2021; 13(10): e18523.
- Saad Abdalla Al-Zawi A, Yin SL, Mahmood B, et al. The oncotype DX recurrence score's impact on the management of oestrogen-positive/human epidermal growth factor receptor 2-negative, low-burden axillary status breast cancer (REHAB study): results of a single centre. Cureus. 2022; 14(7): e27341.
- Cancer Statistics for the UK. Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk (23.06.2023).
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Zhang R, Chen Hj, Wei B, et al. Reproducibility of the Nottingham modification of the Scarff-Bloom-Richardson histological grading system and the complementary value of Ki-67 to this system. Chin Med J (Engl). 2010; 123(15): 1976–1982.
- Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5): 403–410.
- Tsutsumi Y. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol. 2012; 42(5): 375–386.
- Vranic S, Schmitt F, Sapino A, et al. Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol. 2013; 28(11): 1393–1409.
- O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology. 2008; 52(1): 3–10.
- Wu W, Wu M, Peng G, et al. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study. Cancer Med. 2019; 8(18): 7523–7531.
- Mills AM, E Gottlieb C, M Wendroth S, et al. Pure apocrine carcinomas represent a clinicopathologically distinct androgen receptor-positive subset of triple-negative breast cancers. Am J Surg Pathol. 2016; 40(8): 1109–1116.
- Meattini I, Pezzulla D, Saieva C, et al. Triple negative apocrine carcinomas as a distinct subtype of triple negative breast cancer: a case-control study. Clin Breast Cancer. 2018; 18(5): e773–e780.
- Tanaka K, Imoto S, Wada N, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J. 2008; 14(2): 164–168.
- Takeuchi H, Tsuji K, Ueo H, et al. Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women. Breast Cancer Res Treat. 2004; 88(1): 49–54.
- Zhang N, Zhang H, Chen T, et al. Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database. Oncotarget. 2017; 8(15): 24579–24592.
- Al-Zawi AS. The Oncotype DX recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer. Medical Research Journal. 2021; 6(3): 211–216.
- Wysocka J, Adamczyk A, Kruczak A, et al. High Ki-67 expression is a marker of poor survival in apocrine breast carcinoma. Pol J Pathol. 2020; 71(2): 107–119.